Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
genentech
11
×
life sciences
national blog main
national top stories
san francisco top stories
11
×
biotech
boston blog main
boston top stories
san francisco blog main
new york top stories
indiana blog main
indiana top stories
national
new york blog main
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
clinical trials
fda
bristol-myers squibb
cancer
deals
pfizer
roche
gene therapy
ipo
johnson & johnson
What
bio
drug
roundup
fda
cancer
approved
medicines
new
news
approval
biotech
blueprint
companies
drugs
group
known
latest
liver
medical
pharmaceutical
regulatory
ret
roche
therapy
today
address
adu
aiming
alzheimer’s
ambys
annual
appetite
approves
atrophy
august
beats
bids
big
biogen
biopharma
Language
unset
Current search:
genentech
×
" san francisco top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?